Abstract
Prion diseases are fatal neurodegenerative disorders that affect humans and other mammals. The hallmark of these diseases is the conformational change of the cellular prion protein (PrPC) to the misfolded protein capable of propagation and associated with neurodegeneration, named prion (PrPSc). In a strict sense, prion diseases are a consequence of aberrations in the metabolism of the cellular prion protein (PrPC). This brief review addresses current understanding of metabolic disturbances in prion disorders at the cellular, organ and organism level, selectively pointing out some relevant diagnostic and treatment options.
Keywords: Conformational diseases, metabolism, neurodegeneration, PrPC, PrPSc, transmissible spongiform encephalopathies, Prion diseases, Prion, Isoform, Glycoprotein, Misfolding proteins, Amyloid-β, PRNP gene, Translocation, Cytoplasm, Homeostasis, Olfactory discrimination, Embryogenesis, Truncations, Parkinson disease, Alzhemier disease, Tauopathies, Proteinopathies, Follicular dendritic cells, Lymphotoxin, Endocytosis, Monoclonal antibodies, Motif-grated antibodies, Epitope metabolism, ER stress, Oxidatie stress, Creutzfeldt-Jakob disease, Dementia, Myoclonus, Gerstmann-Straussler-Scheinker disease, Ataxia, Magnetic resonance spectroscopy, Pulvinar sign, Myoinositol, Gliosis, PET, Quinacrine, Swansonine, Darwinian evoluition, Anti-idiotypic antibodies
Current Drug Targets
Title: Metabolic Aspects of Prion Diseases: An Overview
Volume: 11 Issue: 10
Author(s): Tanja Vranac and Mara Bresjanac
Affiliation:
Keywords: Conformational diseases, metabolism, neurodegeneration, PrPC, PrPSc, transmissible spongiform encephalopathies, Prion diseases, Prion, Isoform, Glycoprotein, Misfolding proteins, Amyloid-β, PRNP gene, Translocation, Cytoplasm, Homeostasis, Olfactory discrimination, Embryogenesis, Truncations, Parkinson disease, Alzhemier disease, Tauopathies, Proteinopathies, Follicular dendritic cells, Lymphotoxin, Endocytosis, Monoclonal antibodies, Motif-grated antibodies, Epitope metabolism, ER stress, Oxidatie stress, Creutzfeldt-Jakob disease, Dementia, Myoclonus, Gerstmann-Straussler-Scheinker disease, Ataxia, Magnetic resonance spectroscopy, Pulvinar sign, Myoinositol, Gliosis, PET, Quinacrine, Swansonine, Darwinian evoluition, Anti-idiotypic antibodies
Abstract: Prion diseases are fatal neurodegenerative disorders that affect humans and other mammals. The hallmark of these diseases is the conformational change of the cellular prion protein (PrPC) to the misfolded protein capable of propagation and associated with neurodegeneration, named prion (PrPSc). In a strict sense, prion diseases are a consequence of aberrations in the metabolism of the cellular prion protein (PrPC). This brief review addresses current understanding of metabolic disturbances in prion disorders at the cellular, organ and organism level, selectively pointing out some relevant diagnostic and treatment options.
Export Options
About this article
Cite this article as:
Vranac Tanja and Bresjanac Mara, Metabolic Aspects of Prion Diseases: An Overview, Current Drug Targets 2010; 11 (10) . https://dx.doi.org/10.2174/1389450111007011207
DOI https://dx.doi.org/10.2174/1389450111007011207 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neurokinin Peptides and Neurokinin Receptors as Potential Therapeutic Intervention Targets of Basal Ganglia in the Prevention and Treatment of Parkinsons Disease
Current Drug Targets Computational Study and Synthesis of a New Class of Anticonvulsants with 6 Hz Psychomotor Seizure Test Activity: 2-(1,3-benzodioxol-5-yloxy)- N'-[substituted]-acetohydrazides
Medicinal Chemistry Crosstalk between Behavior and Immune System During the Prodromal Stages of Alzheimer`s Disease
Current Pharmaceutical Design Do mtDNA Mutations Participate in the Pathogenesis of Sporadic Parkinsons Disease?
Current Genomics Mechanisms of MDMA (Ecstasy)-Induced Oxidative Stress, Mitochondrial Dysfunction, and Organ Damage
Current Pharmaceutical Biotechnology Advancing Drug Therapy for Brain Tumours: A Current Review of the Pro-inflammatory Peptide Substance P and its Antagonists as Anti-cancer Agents
Recent Patents on CNS Drug Discovery (Discontinued) Management of Inflammation by Natural Polyphenols: A Comprehensive Mechanistic Update
Current Medicinal Chemistry Targeting the Progression of Parkinsons Disease
Current Neuropharmacology Functional Selectivity in Cannabinoid Signaling
Current Molecular Pharmacology A Systematic Review on the Potential Applications of Theranostic Nanoparticles in Diabetes and its Associated Complication Diabetic Neuropathy
Current Nanomedicine Innovations in siRNA Research: A Technology Comes of Age
Recent Patents on Anti-Infective Drug Discovery Association Serum S100B Protein in Alzheimer’s Disease: A Case Control Study from South India
Current Alzheimer Research The Role of the ATP-Binding Cassette Transporter P-Glycoprotein in the Transport of β-Amyloid Across the Blood-Brain Barrier
Current Pharmaceutical Design Plasma Angiotensin-(1-7) is a Potential Biomarker for Alzheimer’s Disease
Current Neurovascular Research The Role of Fatty Acids in the Activity of the Uncoupling Proteins
Current Chemical Biology Bioinformatics Approach to BDNF and BDNF-Related Disorders
Current Neuropharmacology Apoptosis and Acute Brain Ischemia in Ischemic Stroke
Current Vascular Pharmacology Conclusive Article: Sorting the Good from the Bad: The Different Approaches to Predict Cognitive Properties of New Symptomatic Drug Candidates for Neurodegenerative Diseases in Early Development
CNS & Neurological Disorders - Drug Targets Unfoldomics of Human Genetic Diseases: Illustrative Examples of Ordered and Intrinsically Disordered Members of the Human Diseasome
Protein & Peptide Letters Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective
Current Alzheimer Research